Compare GMM & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GMM | ATNM |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 47.1M |
| IPO Year | 2023 | N/A |
| Metric | GMM | ATNM |
|---|---|---|
| Price | $1.29 | $1.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 17.1K | ★ 163.1K |
| Earning Date | 08-18-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $48,171,048.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $42,943.57 |
| P/E Ratio | $0.71 | ★ N/A |
| Revenue Growth | ★ 41.74 | 11.11 |
| 52 Week Low | $1.13 | $1.03 |
| 52 Week High | $4.97 | $2.41 |
| Indicator | GMM | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 65.53 |
| Support Level | $1.13 | $1.48 |
| Resistance Level | $1.41 | $1.69 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 44.43 | 88.89 |
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.